Ray Dalio
BMRN icon

Ray Dalio’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ray Dalio’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.7M Sell
206,911
-23,050
-10% -$1.34M 0.05% 243
2025
Q4 		$13.7M Sell
229,961
-145,722
-39% -$7.93M 0.05% 276
2025
Q3 		$20.3M Buy
375,683
+147,937
+65% +$8.46M 0.08% 196
2025
Q2 		$12.5M Buy
227,746
+104,090
+84% +$6.13M 0.05% 231
2025
Q1 		$8.74M Sell
123,656
-178,824
-59% -$12M 0.04% 281
2024
Q4 		$19.9M Buy
302,480
+160,166
+113% +$10.7M 0.09% 168
2024
Q3 		$10M Buy
142,314
+107,330
+307% +$8.97M 0.06% 262
2024
Q2 		$2.88M Buy
34,984
+31,618
+939% +$2.63M 0.02% 465
2024
Q1 		$294K Sell
3,366
-187,604
-98% -$16.8M ﹤0.01% 657
2023
Q4 		$18.4M Buy
190,970
+29,576
+18% +$2.62M 0.1% 152
2023
Q3 		$14.3M Buy
161,394
+11,418
+8% +$1.02M 0.09% 177
2023
Q2 		$13M Buy
149,976
+25,932
+21% +$2.44M 0.08% 170
2023
Q1 		$12.1M Buy
124,044
+17,665
+17% +$1.83M 0.07% 184
2022
Q4 		$11M Sell
106,379
-1,165
-1% -$109K 0.06% 239
2022
Q3 		$9.12M Buy
107,544
+67,829
+171% +$6.04M 0.05% 266
2022
Q2 		$3.29M Buy
39,715
+20,065
+102% +$1.6M 0.01% 592
2022
Q1 		$1.51M Buy
19,650
+5,667
+41% +$474K 0.01% 736
2021
Q4 		$1.24M Sell
13,983
-27
-0.2% -$2.23K 0.01% 536
2021
Q3 		$1.08M Sell
14,010
-9,171
-40% -$724K 0.01% 503
2021
Q2 		$1.93M Buy
23,181
+9,743
+73% +$772K 0.01% 494
2021
Q1 		$1.01M Buy
+13,438
New +$1.1M 0.01% 313
2016
Q4 		– Sell
-8,926
Closed -$826K – 284
2016
Q3 		$826K Buy
+8,926
New +$841K 0.01% 234
2014
Q2 		– Sell
-48,400
Closed -$3.3M – 319
2014
Q1 		$3.3M Buy
+48,400
New +$3.57M 0.03% 148

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ray Dalio's BMRN Position: Q1 2026 in Review

Ray Dalio reduced its BioMarin Pharmaceuticals (BMRN) stake by 10% in Q1 2026, selling an estimated $1.34M and leaving 206,911 shares worth $11.7M. The position accounts for 0.05% of the portfolio, ranked #243.

Ray Dalio first reported a position in BMRN in Q1 2014 and has held it in 23 quarters since. The position peaked at $20.3M in Q3 2025. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Ray Dalio held 206,911 shares of BioMarin Pharmaceuticals worth $11.7M as of Q1 2026.
  • Ray Dalio sold 23,050 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $1.34M.
  • BioMarin Pharmaceuticals made up 0.05% of Ray Dalio's portfolio in Q1 2026, its #243 holding.
  • Ray Dalio first reported a position in BioMarin Pharmaceuticals in Q1 2014 and has held it in 23 quarters since.
  • Ray Dalio's BioMarin Pharmaceuticals position peaked at $20.3M in Q3 2025.
  • 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.